CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ClearRing offers a minimally invasive treatment for Benign Prostatic Hyperplasia, improving patient outcomes and reducing recovery time. The project aims to validate this innovative solution through clinical trials to enhance men's health care.
Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men.
As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms.
Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide.
The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more toler…
PROARC MEDICAL LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
